GO
Loading...

Medicine

More

  • Do Drugs And Tweets Mix? Wednesday, 23 Sep 2009 | 2:50 PM ET
    Twitter

    The drug biz is abuzz over social media. It's the new frontier. For a lot of PR and corporate communications teams it's all about new media and social media. Some biopharmas, big and small, now have directors of social media. Most are still trying to find their way, but the Food and Drug Administration may soon direct them.

  • The Jury's Out On Dendreon Tuesday, 22 Sep 2009 | 10:41 AM ET

    It's my turn. As fate would have it, on the day of Dendreon's first analyst/investor meeting in years, I have to report for jury duty this Thursday in Newark, NJ. But apparently it wouldn't have mattered if I were available anyway or wanted to send a surrogate.

  • No Constipation In Biopharma Newsflow Monday, 21 Sep 2009 | 12:29 PM ET

    When it rains, it pours. I mean, what a crazy Monday for deals and data in biopharma.

  • Iin light of evidence that some drug makers have gone to great lengths to turn scientific articles into marketing vehicles for their products, some influential medical editors are cracking down on industry-financed ghostwriting. And they are getting help from some members of Congress.

  • Arena Adds Volume Friday, 18 Sep 2009 | 1:33 PM ET

    There! I resisted writing a blog headline that attempts some tired play on words with the Arena Pharmaceuticals' clinical trial acronyms BLOSSOM and BLOOM.

  • A Rise For Biopharma In The Fall? Wednesday, 16 Sep 2009 | 12:14 PM ET

    Today is the 16th annual "Newsmakers in Biotech" event put on by Thomson Reuters and BioCentury.

  • Auxilium, Pfizer Could Get A Helping Hand Tuesday, 15 Sep 2009 | 4:51 PM ET

    Tomorrow I'll be hanging out at the BioCentury/Thomson Reuters "Newsmakers in the Biotech Industry" conference in NYC, so I won't be able to monitor the webcast of an FDA panel meeting for a most intriguing drug.

  • A Ghost Of A Chance In Pancreatic Cancer Tuesday, 15 Sep 2009 | 12:24 PM ET
    Patrick Swayze

    Patrick Swayze is sadly a statistic. He is one of an estimated 35,000 people in the United States who will die from pancreatic cancer this year. Several companies are working on drugs for the disease, but the path is littered with failures.

  • Will Pot TV Show Bring 'High' Ratings? Tuesday, 15 Sep 2009 | 10:26 AM ET
    Marijuana

    Tips for cultivating marijuana. Testimonials by patients about its medical benefits. Cannabis cooking lessons. Even citations for award-winning strains of pot. Viewers here can now watch, every week, what amounts to a pro-weed news program.

  • Lilly: 'Let's Get Small'-er Monday, 14 Sep 2009 | 1:41 PM ET

    Surely, Eli Lilly didn't throw it's restructuring plan together in a couple of weeks, but it was just the end of last month when Leerink Swann analyst Seamus Fernandez said LLY needed to cut costs and/or do a big deal. So, kudos to him for getting out ahead of it.

  • Mylan Parts Ways With PR Tradition Thursday, 10 Sep 2009 | 9:53 AM ET
    Mylan Laboratories Inc. headquarters

    Usually when a company announces an executive departure the news comes out in a press release with a header along the lines of , "So-and-so to retire, search begins for successor," or, "XYZ Corp. CEO resigns, interim CEO appointed," etc.

  • The Qnexa Question Wednesday, 9 Sep 2009 | 5:22 PM ET
    Qnexa

    Some analysts had been telling clients recently that they thought Vivus' diet drug Qnexa could take the lead in the three-contestant race to get the next prescription diet pill on the market. But they didn't think it would take such a commanding lead.

  • The Roche Management Merry-Go-Round Tuesday, 8 Sep 2009 | 9:40 AM ET

    Talk about a short tenure. Only eight months after Roche installed him as CEO of Genentech, Pascal Soriot is moving on (up?) to become COO of Roche's Pharma Division.

  • Pfizer's Big News. Or Is It? Wednesday, 2 Sep 2009 | 2:17 PM ET

    Lost in the coverage of the Pfizer-Wyeth deal that day, but nonetheless disclosed in the company's simultaneous earnings release back on January 26th of this year, PFE revealed it had taken a $2.3 billion charge for a pending settlement over marketing.

  • Cancer Drugs Mean Big Profits, Big Risks for Big Pharma Wednesday, 2 Sep 2009 | 1:51 PM ET
    Big Pharma

    Virtually every large pharmaceutical company seems to have discovered cancer, and a substantial portion of the smaller biotechnology companies are focused on it as well. Together, the companies are pouring billions of dollars into developing cancer drugs.

  • Analyst Says Lilly's A Loser Monday, 31 Aug 2009 | 8:55 AM ET

    After a long delay, Eli Lilly finally launched its new bloodthinner Effient just this month. But analysts are already buzzing about what's next.

  • Chadwick: Rationing Health Care is Scary Thursday, 27 Aug 2009 | 1:50 PM ET

    Reading Betsy McCaughey’s op-ed article in today’s Wall Street Journal, I understand fully why the elderly are so scared about the possibility of a nationalized health care system.

  • Glaxo Comes To The Defense Of Its alli Wednesday, 26 Aug 2009 | 9:52 AM ET

    British drugmaker GlaxoSmithKline is trying to keep from having to tighten its belt over new safety concerns with its weightloss pill, alli

  • Real Choice? It's Off Limits in Most Health-Care Bills Wednesday, 26 Aug 2009 | 8:22 AM ET
    doctor

    Real choice is not part of the bills moving through the Democratic-led Congress; even if the much-debated government-run insurance plan was created, it would not be available to most people who already have coverage.

  • Novartis Attackers Hold Ashes Hostage Tuesday, 25 Aug 2009 | 10:02 AM ET
    Graveyard that contains the family graves of Daniel Vasella, CEO/Chairman of Novartis.

    Am I missing something? Or is this not the way to go about advancing your cause?